Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.
Samuel A. Funt(Memorial Sloan Kettering Cancer Center), Rohit K. Jain(Moffitt Cancer Center), Petros Grivas(Seattle Cancer Care Alliance), Mayank Rao, Daniel A. Vaena(West Cancer Center), Kimberly Tipton(CytomX Therapeutics (United States)), Alison Forgie, Sophia Randolph(Pfizer (United States)), Grace An, Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Tian Zhang(Duke Medical Center), Xīn Gào(Qingdao University), Feng Jin, Harry Liu, Athanasios C. Tsiatis(Loxo Oncology at Lilly (United States))
Cited by 2
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k